Search

Dr Reddy's Laboratories Ltd-ADR

Slēgts

SektorsVeselības aprūpe

12.11 0.41

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

11.84

Max

12.1

Galvenie mērījumi

By Trading Economics

Ienākumi

2.1B

4.3B

Pārdošana

4.9B

81B

P/E

Sektora vidējais

28.707

64.641

EPS

0.06

Dividenžu ienesīgums

0.71

Peļņas marža

5.356

Darbinieki

27,527

EBITDA

-5.8B

3B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+36.54% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

0.71%

2.31%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-629M

9.8B

Iepriekšējā atvēršanas cena

11.7

Iepriekšējā slēgšanas cena

12.11

Ziņu noskaņojums

By Acuity

50%

50%

151 / 340 Rangs Healthcare

Dr Reddy's Laboratories Ltd-ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. aug. 23:56 UTC

News

Diversified Healthcare Trust reported second-quarter FFO of $0.16, exceeding estimates. Revenue fell short at $365.39 million, contributing to a decline in after-market trading.

2026. g. 3. aug. 23:56 UTC

News

First Solar Inc reported second-quarter revenue of $1.06 billion and a net profit of $423 million. Shares are higher in after-hours trading.

2026. g. 3. aug. 23:52 UTC

Social Media
Correlated Moves
News

Microsoft shares are lower in after-market hours amid a class action lawsuit alleging misrepresentation of its Copilot products' performance and competitive position.

2026. g. 3. aug. 23:51 UTC

News

Marvell Technology plans a conference call for August 27, 2026, and an Investor Day on October 6, 2026. Shares are higher in after-market trading.

2026. g. 3. aug. 23:51 UTC

News

Rivian Automotive raises 2026 capital expenditure guidance to $1.7B-$1.8B, shares trade higher in after-market hours amid focus on cost management and production scaling.

2026. g. 3. aug. 23:51 UTC

News

JELD-WEN Holding Inc. reported second-quarter revenue of $817.8 million, exceeding forecasts. The company raised its full-year revenue guidance, boosting after-market trading sentiment.

2026. g. 3. aug. 23:51 UTC

Social Media
News

Palantir Technologies reported Q2 revenue of $1.94 billion, exceeding expectations. Shares rose sharply in after-market hours following strong earnings and raised guidance.

2026. g. 3. aug. 23:51 UTC

Social Media
News

Snap Inc. reported a narrower net loss of $163.96 million and revenue of $1.60 billion, exceeding expectations. Shares rose during after-market trading.

2026. g. 3. aug. 23:46 UTC

News

Novavax Inc is advancing in after-market trading as it shifts focus to licensing its Matrix-M adjuvant, attracting positive retail investor sentiment ahead of earnings.

2026. g. 3. aug. 23:46 UTC

News

CVS Health shares rose in after-market hours following a survey showing increased provider-payer trust scores and improved perceptions of digital tools in healthcare.

2026. g. 3. aug. 23:46 UTC

News

Alexandria Real Estate Equities reported a narrower net loss and FFO of $1.73, exceeding estimates. Shares traded higher in after-market hours.

2026. g. 3. aug. 23:46 UTC

Correlated Moves
News

Nova Ltd's after-market shares are higher, bolstered by strong analyst sentiment and a consensus price target of $603.38, reflecting a potential 54.4% return.

2026. g. 3. aug. 23:46 UTC

News

Realty Income Corp reported first-quarter revenue of nearly $1.55 billion, with adjusted funds from operations increasing to $1.06 billion. Shares were roughly flat after-market.

2026. g. 3. aug. 23:41 UTC

News

Teladoc Health remains effectively unchanged in after-market trading. Citigroup lowered its price target from $11.00 to $7.50 while maintaining a "neutral" rating.

2026. g. 3. aug. 23:41 UTC

News

Addus Homecare Corp reported Q2 revenue of $377.4 million and adjusted EPS of $1.73. Shares declined after the earnings announcement amid mixed market reactions.

2026. g. 3. aug. 23:41 UTC

News

Hims & Hers Health shares are higher in after-market trading, following positive growth insights despite facing a lawsuit from the Federal Trade Commission.

2026. g. 3. aug. 23:41 UTC

Correlated Moves
News

DA Davidson raised its price target for First Business Financial Services to $80, contributing to higher shares in after-market trading.

2026. g. 3. aug. 23:41 UTC

News

Karyopharm Therapeutics shares are lower in after-market hours following the grant of restricted stock units to a new employee, raising potential dilution concerns.

2026. g. 3. aug. 23:41 UTC

News

Andersons Inc. shares rise in after-market trading following strong Q2 results, with adjusted net income of $73.6 million exceeding expectations.

2026. g. 3. aug. 23:41 UTC

Social Media
News

BWX Technologies shares are lower in after-market hours following a revenue miss of $901.6 million and a divestiture of its medical business to Nordic Capital.

2026. g. 3. aug. 23:41 UTC

Social Media
News

Williams Companies announced an agreement to acquire Momentum Midstream for up to $5.5 billion, boosting its natural gas infrastructure and supporting Gulf Coast demand.

2026. g. 3. aug. 23:41 UTC

News

Ichor Holdings shares lower in after-market trading following a revenue miss of $294.8 million and EPS of $0.03, below expectations.

2026. g. 3. aug. 23:31 UTC

News

Biomarin Pharmaceutical shares are lower in after-market hours amid concerns over stagnant operating margins and below-average returns on capital, raising investor caution.

2026. g. 3. aug. 23:31 UTC

News

Ameresco shares rose in after-market trading following strong Q2 results, with revenues of $515.5 million exceeding expectations and a record $1.8 billion in new project awards.

2026. g. 3. aug. 23:31 UTC

News

UBS raised its price target on Colgate-Palmolive Co to $109, maintaining a Buy rating. Shares are trading higher in after-market hours.

2026. g. 3. aug. 23:31 UTC

Social Media
News

Grab Holdings reported strong Q2 results, with earnings per share of 6 cents and revenue of $997 million. Shares are higher in after-market hours.

2026. g. 3. aug. 23:31 UTC

News

Ultra Clean Holdings reported Q2 net income of $11.9 million and revenue of $644.9 million, raising its Q3 outlook to between $700 million and $750 million.

2026. g. 3. aug. 23:26 UTC

Social Media
News

Vertex Pharmaceuticals reported second-quarter revenue of $3.33 billion, exceeding estimates. The company raised its full-year guidance to between $13.1 billion and $13.2 billion.

2026. g. 3. aug. 23:21 UTC

News

Banner Corp announces a buyback of up to 1.7 million shares, aiming to enhance long-term shareholder value. Shares are higher in after-market trading.

2026. g. 3. aug. 23:21 UTC

News

Inspire Medical Systems reported Q2 adjusted EPS of $0.14, exceeding expectations. The company raised its full-year EPS guidance to between $1.05 and $1.45.

Salīdzinājums

Cenas izmaiņa

Dr Reddy's Laboratories Ltd-ADR Prognoze

Cenas mērķis

By TipRanks

36.54% augšup

Prognoze 12 mēnešiem

Vidējais 16.18 USD  36.54%

Augstākais 16.178 USD

Zemākais 16.178 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Dr Reddy's Laboratories Ltd-ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

1

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

151 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
help-icon Live chat